Want to see GDRX full AI Analyst Report?
Top Page
GoodRx Holdings
(NASDAQ:GDRX)
Select Model
Select Model
Rating:66Neutral
Price Target:
$4.00
▲(35.14% Upside)
Action:Reiterated
Date:08/07/26
The score is primarily supported by strong and improving cash generation and a constructive earnings call with raised full-year guidance (Pharma Direct and subscriptions driving growth). Technicals also support the rating with bullish trend/momentum, though overbought signals add near-term risk. The biggest constraint is valuation (high P/E) alongside mixed underlying fundamentals, especially the sharp TTM revenue decline and still-thin profitability.
Positive Factors
Strong and improving cash generation
Sustained positive operating and free cash flow provides funding for product investment, supports financial resilience, and indicates stronger cash conversion than the company’s thin reported profitability alone would suggest.
Negative Factors
Sharp revenue decline and thin profitability
The steep top-line contraction shows that the business transition has not yet produced consistent aggregate growth. Thin profitability leaves less buffer to absorb execution challenges or investment needs.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong and improving cash generation
Sustained positive operating and free cash flow provides funding for product investment, supports financial resilience, and indicates stronger cash conversion than the company’s thin reported profitability alone would suggest.
Read all positive factors
GoodRx Holdings Key Performance Indicators (KPIs)
Any
Monthly Active Consumers
Shows the number of unique users engaging with the platform each month, highlighting user retention, platform popularity, and potential for monetization.
Shows the number of unique users engaging with the platform each month, highlighting user retention, platform popularity, and potential for monetization.
Data provided by:
The Fly
The FlyGoodRx Holdings (GDRX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.17B
Dividend YieldN/A
Average Volume (3M)1.02M
Price to Earnings (P/E)65.4
Beta (1Y)1.08
Revenue Growth-1.83%
EPS Growth-48.77%
CountryUS
Employees697
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)0.05
Shares Outstanding107,181,200
10 Day Avg. Volume911,183
30 Day Avg. Volume1,022,773
Financial Highlights & Ratios
PEG Ratio0.31
Price to Book (P/B)1.57
Price to Sales (P/S)1.21
P/FCF Ratio5.87
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$4.14Price Target Upside39.86% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
EPS Forecast (FY)0.3
Revenue Forecast (FY)$799.78M
GoodRx Holdings Business Overview & Revenue Model
Company Description
GoodRx Holdings, Inc. provides American consumers with essential resources and tools to compare and ultimately lower the cost of their prescription medications. The company operates a digital platform dedicated to price comparison, delivering cust...
How the Company Makes Money
GoodRx primarily makes money by monetizing prescription transactions and related healthcare services facilitated through its platform. A major revenue stream is prescription-related revenue tied to its discount programs: when a consumer uses a Goo...
GoodRx Holdings Earnings Call Summary
Earnings Call Date:Aug 05, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 10, 2026
Earnings Call Sentiment Positive
The call emphasized strong execution and visible, high-growth revenue engines (Pharma Direct and subscriptions) with meaningful beats and raised full-year guidance. These positives were tempered by declines in monthly active consumers, moderation of traditional prescription transaction revenue and limited disclosure of prescription-level KPIs during a strategic transition. Management framed the shifts as intentional investments in more durable, higher-LTV revenue streams and signaled confidence in sustained growth, while acknowledging some short-term metric and disclosure trade-offs.Positive Updates
Strong Quarterly Financial Results
Revenue of $200.4 million and adjusted EBITDA of $63.7 million in Q2 2026, with an adjusted EBITDA margin of 31.8%.
Negative Updates
Decline in Monthly Active Consumers
Monthly active consumers totaled 5.0 million, down 12% year-over-year and down sequentially, reflecting seasonality and a deliberate shift of product and marketing investment toward subscriptions.
Read all updates
Q2-2026 Updates
Positive
Negative
Strong Quarterly Financial Results
Revenue of $200.4 million and adjusted EBITDA of $63.7 million in Q2 2026, with an adjusted EBITDA margin of 31.8%.
Read all positive updates
Company Guidance
GoodRx raised its full-year revenue guidance to $790–$805 million and its adjusted EBITDA guidance to $240–$250 million, citing strong first-half results (Q2 revenue $200.4M; adjusted EBITDA $63.7M; adj. EBITDA margin 31.8%) and an expectation that Pharma Direct and subscriptions will more than offset declines in prescription-transaction revenue in H2, with midpoint results returning the company to year-over-year revenue growth earlier than previously anticipated. Key Q2 metrics included Pharma Direct revenue of $61.6M (up 76% YoY, 18% QoQ; ~31% of revenue), prescription-transaction revenue of $106.4M, subscription revenue of $28.5M (up 39% YoY) and 5.0M monthly active consumers (down 12% YoY); subscription plans rose 14% YoY. Management also cited scale and engagement metrics supporting the outlook: >135 consumer-direct pricing programs, ~280M annual site visits, and e-commerce live at nearly 6,000 pharmacies.GoodRx Holdings Financial Statement Overview
Summary
Income Statement
55
Neutral
Balance Sheet
62
Positive
Cash Flow
78
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 785.23M | 796.85M | 792.32M | 750.26M | 766.55M | 745.42M |
| Gross Profit | 691.40M | 739.26M | 744.11M | 683.34M | 701.48M | 698.71M |
| EBITDA | 148.58M | 184.36M | 153.92M | 108.82M | 65.19M | 48.00M |
| Net Income | 16.25M | 30.44M | 16.39M | -8.87M | -32.83M | -25.25M |
Balance Sheet | ||||||
| Total Assets | 2.34B | 1.40B | 1.39B | 1.59B | 1.60B | 1.61B |
| Cash, Cash Equivalents and Short-Term Investments | 296.11M | 261.82M | 448.35M | 672.30M | 757.16M | 941.11M |
| Total Debt | 538.95M | 542.81M | 543.39M | 711.07M | 717.02M | 702.33M |
| Total Liabilities | 1.70B | 787.80M | 663.41M | 826.84M | 789.80M | 775.95M |
| Stockholders Equity | 647.60M | 616.26M | 724.66M | 761.96M | 814.83M | 831.68M |
Cash Flow | ||||||
| Free Cash Flow | 145.75M | 164.38M | 113.55M | 82.53M | 91.57M | 144.32M |
| Operating Cash Flow | 201.58M | 167.90M | 183.89M | 138.29M | 146.78M | 178.78M |
| Investing Cash Flow | -85.82M | -119.96M | -70.35M | -55.77M | -210.50M | -178.73M |
| Financing Cash Flow | -100.96M | -234.47M | -337.50M | -167.40M | -120.23M | -30.53M |
GoodRx Holdings Technical Analysis
Positive
2.96
Price Trends
3.15
Positive
2.83
Positive
2.67
Positive
Market Momentum
0.11
Positive
53.77
Neutral
8.23
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GDRX, the sentiment is Positive. The current price of 2.96 is below the 20-day moving average (MA) of 3.50, below the 50-day MA of 3.15, and above the 200-day MA of 2.67, indicating a neutral trend. The MACD of 0.11 indicates Positive momentum. The RSI at 53.77 is Neutral, neither overbought nor oversold. The STOCH value of 8.23 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GDRX.
GoodRx Holdings Risk Analysis
GoodRx Holdings disclosed 2 risk factors in its most recent earnings report. GoodRx Holdings reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
GoodRx Holdings Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | $106.23M | 35.82 | 16.56% | ― | 15.07% | ― | |
70 Outperform | $722.58M | 76.81 | 2.79% | ― | 14.05% | ― | |
68 Neutral | $1.47B | 354.64 | 1.84% | ― | 47.63% | ― | |
66 Neutral | $1.17B | 65.40 | 2.61% | ― | -1.83% | -48.77% | |
55 Neutral | $202.74M | -2.50 | -33.27% | ― | -19.00% | 40.98% | |
52 Neutral | $1.13B | -6.26 | -13.08% | ― | -2.08% | 16.88% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
GDRX
GoodRx Holdings
3.65
-0.85
-18.89%
CCLD
CareCloud
2.64
-1.07
-28.84%
TDOC
Teladoc
6.33
-1.41
-18.22%
PHR
Phreesia
11.60
-20.39
-63.74%
AMWL
American Well
11.92
4.97
71.51%
OMDA
Omada Health, Inc.
23.96
0.64
2.74%
GoodRx Holdings Corporate Events
Executive/Board ChangesShareholder Meetings
GoodRx Stockholders Approve Directors, Auditor and Executive Pay
Positive
Jun 18, 2026
On June 16, 2026, GoodRx Holdings, Inc. held its annual meeting of stockholders, with holders of its dual-class shares representing about 99.4% of total voting power present in person or by proxy as of the April 20, 2026 record date. Stockholders ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.